Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

In September of last year, the FDA said it had begun exploring the potential health effects of various metals that have been ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug ...

Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as ...

After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of ...

Last December, the FDA published its final guidance on predetermined change control plans, or PCCPs, with recommendations to ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for ...